

Bryan Lau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3523295/publications.pdf>

Version: 2024-02-01

81
papers

3,912
citations

279798

23
h-index

133252

59
g-index

84
all docs

84
docs citations

84
times ranked

7388
citing authors

#	ARTICLE	IF	CITATIONS
1	Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, e477-e486.	5.8	29
2	Telemedicine and visit completion among people with HIV during the coronavirus disease 2019 pandemic compared with pre-pandemic. <i>Aids</i> , 2022, 36, 355-362.	2.2	18
3	The Association Between HIV Status, Estradiol, and Sex Hormone Binding Globulin Among Premenopausal Women in the Women's Interagency HIV Study. <i>Journal of Women's Health</i> , 2022, 31, 183-193.	3.3	4
4	COVID-19 and the HIV continuum in people living with HIV enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts. <i>Drug and Alcohol Dependence</i> , 2022, 241, 109355.	3.2	9
5	Early Outpatient Treatment for Covid-19 with Convalescent Plasma. <i>New England Journal of Medicine</i> , 2022, 386, 1700-1711.	27.0	194
6	The relationship of alcohol and other drug use during the COVID-19 pandemic among people with or at risk of HIV; A cross-sectional survey of people enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts. <i>Drug and Alcohol Dependence</i> , 2022, 241, 109382.	3.2	4
7	Meta-analysis under imbalance in measurement of confounders in cohort studies using only summary-level data. <i>BMC Medical Research Methodology</i> , 2022, 22, 143.	3.1	2
8	All-Cause and Cardiovascular Disease Mortality Among Breast Cancer Survivors in CLUE II, a Long-Standing Community-Based Cohort. <i>Journal of the National Cancer Institute</i> , 2021, 113, 137-145.	6.3	51
9	Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, 1900-1909.	5.8	22
10	Estimating the prevalence of and characteristics associated with prescription opioid diversion among a clinic population living with HIV: Indirect and direct questioning techniques. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108398.	3.2	2
11	Changing Patterns of Alcohol Use and Probability of Unsuppressed Viral Load Among Treated Patients with HIV Engaged in Routine Care in the United States. <i>AIDS and Behavior</i> , 2021, 25, 1072-1082.	2.7	11
12	The Patient Reported Outcomes as a Clinical Tool (PROACT) Pilot Study: What Can be Gained by Sharing Computerized Patient-Reported Mental Health and Substance Use Symptoms with Providers in HIV Care?. <i>AIDS and Behavior</i> , 2021, 25, 2963-2972.	2.7	5
13	A learning algorithm for predicting mental health symptoms and substance use. <i>Journal of Psychiatric Research</i> , 2021, 134, 22-29.	3.1	0
14	Combining Effect Estimates Across Cohorts and Sufficient Adjustment Sets for Collaborative Research. <i>Epidemiology</i> , 2021, 32, 421-424.	2.7	2
15	Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 663-670.	2.1	3
16	Decreased Alcohol Consumption in an Implementation Study of Computerized Brief Intervention among HIV Patients in Clinical Care. <i>AIDS and Behavior</i> , 2021, 25, 4074-4084.	2.7	12
17	The Effect of Buprenorphine on Human Immunodeficiency Virus Viral Suppression. <i>Clinical Infectious Diseases</i> , 2021, 73, 1951-1956.	5.8	12
18	Abstract 30: Impact of race, sex and age on the risk of pancreatic cancer in new onset diabetics in real-world data., 2021, , .		0

#	ARTICLE	IF	CITATIONS
19	Drug and alcohol use among people living with HIV in care in the United States by geographic region. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 1569-1576.	1.2	15
20	Optimizing respondent-driven sampling to find undiagnosed HIV-infected people who inject drugs. <i>Aids</i> , 2021, 35, 485-494.	2.2	4
21	48. Time Between Viral Loads for Suppressed and Non-Suppressed People with HIV During the COVID-19 Pandemic Compared to Pre-Pandemic. <i>Open Forum Infectious Diseases</i> , 2021, 8, S34-S35.	0.9	1
22	Measuring neighbourhood social and economic change for urban health studies. <i>Urban Studies</i> , 2020, 57, 1301-1319.	3.7	5
23	Validation of a Risk Equation Predicting Hemodialysis Arteriovenous Fistula Primary Failure in Elderly. <i>American Journal of Nephrology</i> , 2020, 51, 17-23.	3.1	2
24	Short Communication: Differences in 5-Year Survival After Cancer Diagnosis Between HIV Clinic Enrollees and the General U.S. Population. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 116-118.	1.1	2
25	Immune Status and Associated Mortality After Cancer Treatment Among Individuals With HIV in the Antiretroviral Therapy Era. <i>JAMA Oncology</i> , 2020, 6, 227.	7.1	23
26	Arteriovenous Fistula Placement, Maturation, and Patency Loss in Older Patients Initiating Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2020, 76, 480-489.e1.	1.9	13
27	Economic Burden Among Gay, Bisexual, and Other Men Who Have Sex With Men Living With HIV or Living Without HIV in the Multicenter AIDS Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 436-443.	2.1	2
28	Selecting important predictors for arteriovenous fistula maturation in older hemodialysis patients by using random survival forests. <i>Seminars in Dialysis</i> , 2020, 33, 148-155.	1.3	1
29	A comparison of cancer stage at diagnosis and treatment initiation between enrollees in an urban HIV clinic and SEER. <i>Cancer Causes and Control</i> , 2020, 31, 511-516.	1.8	1
30	Deployment of convalescent plasma for the prevention and treatment of COVID-19. <i>Journal of Clinical Investigation</i> , 2020, 130, 2757-2765.	8.2	649
31	Recent Substance Use and Probability of Unsuppressed HIV Viral Load Among Persons on Antiretroviral Therapy in Continuity Care. <i>American Journal of Epidemiology</i> , 2019, 188, 1830-1837.	3.4	15
32	Ancillary service needs among persons new to HIV care and the relationship between needs and late presentation to care. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1131-1139.	1.2	3
33	Pregnancy Outcomes in the Era of Universal Antiretroviral Treatment in Sub-Saharan Africa (POISE) Tj ETQq1 1 0.784314 rgBTJ /Overlock	2.1	23
34	Association of History of Injection Drug Use with External Cause-Related Mortality Among Persons Linked to HIV Care in an Urban Clinic, 2001â€“2015. <i>AIDS and Behavior</i> , 2019, 23, 3286-3293.	2.7	10
35	Medicaid trends in prescription opioid and non-opioid use by HIV status. <i>Drug and Alcohol Dependence</i> , 2019, 197, 141-148.	3.2	15
36	Censoring for Loss to Follow-up in Time-to-event Analyses of Composite Outcomes or in the Presence of Competing Risks. <i>Epidemiology</i> , 2019, 30, 817-824.	2.7	8

#	ARTICLE	IF	CITATIONS
37	Death after diagnosis of noncommunicable disease comorbid conditions, stratified by injection drug use. <i>Aids</i> , 2019, 33, 285-293.	2.2	0
38	Alcohol Use Patterns and Subsequent Sexual Behaviors Among Women, Men who have Sex with Men and Men who have Sex with Women Engaged in Routine HIV Care in the United States. <i>AIDS and Behavior</i> , 2019, 23, 1634-1646.	2.7	16
39	Do Symptoms of Depression Interact with Substance Use to Affect HIV Continuum of Care Outcomes?. <i>AIDS and Behavior</i> , 2019, 23, 580-591.	2.7	22
40	An Environmental influences on Child Health Outcomes viewpoint of data analysis centers for collaborative study designs. <i>Current Opinion in Pediatrics</i> , 2018, 30, 269-275.	2.0	21
41	When to Censor?. <i>American Journal of Epidemiology</i> , 2018, 187, 623-632.	3.4	46
42	Collaborative, pooled and harmonized study designs for epidemiologic research: challenges and opportunities. <i>International Journal of Epidemiology</i> , 2018, 47, 654-668.	1.9	45
43	Predictors of Longitudinal Trajectories of Alcohol Consumption in People with HIV. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 561-570.	2.4	23
44	Measurement of Current Substance Use in a Cohort of HIV-Infected Persons in Continuity HIV Care, 2007-2015. <i>American Journal of Epidemiology</i> , 2018, 187, 1970-1979.	3.4	20
45	High-Risk Prescription Opioid Use Among People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 283-290.	2.1	26
46	Time Spent with HIV Viral Load > 1500 Copies/mL Among Persons Engaged in Continuity HIV Care in an Urban Clinic in the United States, 2010-2015. <i>AIDS and Behavior</i> , 2018, 22, 3443-3450.	2.7	10
47	Estimating multiple time-fixed treatment effects using a semi-Bayes semiparametric marginal structural Cox proportional hazards regression model. <i>Biometrical Journal</i> , 2018, 60, 100-114.	1.0	2
48	Influence of Injection Drug Use-Related HIV Acquisition on CD4 Response to First Antiretroviral Therapy Regimen Among Virally Suppressed Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 317-324.	2.1	1
49	Beyond binary retention in HIV care. <i>Aids</i> , 2018, 32, 2217-2225.	2.2	29
50	Refraction and Change in Refraction Over a 20-Year Period in the Beaver Dam Eye Study. , 2018, 59, 4518.		18
51	Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework. <i>American Journal of Epidemiology</i> , 2018, 187, 316-325.	3.4	13
52	An application of restricted mean survival time in a competing risks setting: comparing time to ART initiation by injection drug use. <i>BMC Medical Research Methodology</i> , 2018, 18, 27.	3.1	27
53	Missingness in the Setting of Competing Risks: from Missing Values to Missing Potential Outcomes. <i>Current Epidemiology Reports</i> , 2018, 5, 153-159.	2.4	10
54	Epidemiology at a time for unity. <i>International Journal of Epidemiology</i> , 2018, 47, 1366-1371.	1.9	6

#	ARTICLE	IF	CITATIONS
55	Mechanisms Underlying HIV-Associated Noninfectious Lung Disease. <i>Chest</i> , 2017, 152, 1053-1060.	0.8	24
56	Prevalence and Factors Associated with Hazardous Alcohol Use Among Persons Living with HIV Across the US in the Current Era of Antiretroviral Treatment. <i>AIDS and Behavior</i> , 2017, 21, 1914-1925.	2.7	102
57	Marijuana use and HIV treatment outcomes among PWH receiving care at an urban HIV clinic. <i>Journal of Substance Abuse Treatment</i> , 2017, 82, 102-106.	2.8	18
58	Bias Due to Confounders for the Exposure-Competing Risk Relationship. <i>Epidemiology</i> , 2017, 28, 20-27.	2.7	38
59	Not all non-drinkers with HIV are equal: demographic and clinical comparisons among current non-drinkers with and without a history of prior alcohol use disorders [*] . <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 177-184.	1.2	12
60	Differential effects of perceived stress on alcohol consumption in moderate versus heavy drinking HIV-infected women. <i>Drug and Alcohol Dependence</i> , 2017, 178, 380-385.	3.2	11
61	Retention, Antiretroviral Therapy Use and Viral Suppression by History of Injection Drug Use Among HIV-Infected Patients in an Urban HIV Clinical Cohort. <i>AIDS and Behavior</i> , 2017, 21, 1016-1024.	2.7	30
62	The Effect of a Multi-Level Intervention on the Initiation of Antiretroviral Therapy (ART) among HIV-Infected Men Who Inject Drugs and Were Diagnosed Late in Thai Nguyen, Vietnam. <i>PLoS ONE</i> , 2016, 11, e0161718.	2.5	9
63	Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIV. <i>AIDS Patient Care and STDs</i> , 2016, 30, 200-207.	2.5	28
64	A longitudinal, HIV care continuum. <i>Aids</i> , 2016, 30, 2227-2234.	2.2	49
65	Heavy Alcohol Use Is Associated With Worse Retention in HIV Care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 419-425.	2.1	80
66	Estimation of the Standardized Risk Difference and Ratio in a Competing Risks Framework: Application to Injection Drug Use and Progression to AIDS After Initiation of Antiretroviral Therapy. <i>American Journal of Epidemiology</i> , 2015, 181, 238-245.	3.4	54
67	End-Stage Renal Disease Among HIV-Infected Adults in North America. <i>Clinical Infectious Diseases</i> , 2015, 60, 941-949.	5.8	142
68	Allowing Physicians to Choose the Value of Compensation for Participation in a Web-Based Survey: Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2015, 17, e189.	4.3	10
69	HIV Viremia and T-Cell Activation Differentially Affect the Performance of Glomerular Filtration Rate Equations Based on Creatinine and Cystatin C. <i>PLoS ONE</i> , 2013, 8, e82028.	2.5	35
70	Parametric mixture models to evaluate and summarize hazard ratios in the presence of competing risks with time-dependent hazards and delayed entry. <i>Statistics in Medicine</i> , 2011, 30, 654-665.	1.6	23
71	Alcohol Consumption Among HIV-Infected Women: Impact on Time to Antiretroviral Therapy and Survival. <i>Journal of Women's Health</i> , 2011, 20, 279-286.	3.3	58
72	Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study. <i>AIDS Research and Therapy</i> , 2010, 7, 25.	1.7	2

#	ARTICLE	IF	CITATIONS
73	Competing Risk Regression Models for Epidemiologic Data. <i>American Journal of Epidemiology</i> , 2009, 170, 244-256.	3.4	984
74	Evaluation of Human Immunodeficiency Virus Biomarkers. <i>Epidemiology</i> , 2009, 20, 664-672.	2.7	11
75	Evaluating competing adverse and beneficial outcomes using a mixture model. <i>Statistics in Medicine</i> , 2008, 27, 4313-4327.	1.6	18
76	Risk of Non-AIDS-Related Mortality May Exceed Risk of AIDS-Related Mortality Among Individuals Enrolling Into Care With CD4+ Counts Greater Than 200 Cells/mm ³ . <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 179-187.	2.1	111
77	Interval and Clinical Cohort Studies: Epidemiological Issues. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 769-776.	1.1	53
78	C-Reactive Protein Is a Marker for Human Immunodeficiency Virus Disease Progression. <i>Archives of Internal Medicine</i> , 2006, 166, 64.	3.8	178
79	Hazardous Alcohol Use. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 411-417.	2.1	278
80	Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 620-5.	2.1	13
81	Methods for the Analysis of Continuous Biomarker Assay Data With Increased Sensitivity. <i>Epidemiology</i> , 2004, 15, 724-732.	2.7	6